ASTX727 in Patients with Hepatic Impairment
A Phase 1b, Open-label, Parallel Group, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Decitabine and Cedazuridine (ASTX727) in Cancer Patients With Moderate and Severe Hepatic Impairment
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 1
- Enrollment
- 27 patients (estimated)
- Sponsors
- Taiho Oncology, Inc.
- Tags
- Chemotherapy, Hypomethylating Agents (HMA)
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 2117
- NCT Identifier
- NCT04953910
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.